1. Home
  2. MRKR vs ACCL Comparison

MRKR vs ACCL Comparison

Compare MRKR & ACCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

22.5M

Sector

Health Care

ML Signal

HOLD

Logo Acco Group Holdings Limited Ordinary Shares

ACCL

Acco Group Holdings Limited Ordinary Shares

HOLD

Current Price

$2.15

Market Cap

26.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRKR
ACCL
Founded
1999
2009
Country
United States
Hong Kong
Employees
N/A
22
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
22.5M
26.9M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
MRKR
ACCL
Price
$1.21
$2.15
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
62.4K
22.9K
Earning Date
05-14-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
33.61
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$936.27
N/A
P/E Ratio
N/A
$17.13
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$1.23
52 Week High
$2.46
$5.00

Technical Indicators

Market Signals
Indicator
MRKR
ACCL
Relative Strength Index (RSI) 33.81 74.81
Support Level $1.17 $1.31
Resistance Level $1.52 $2.16
Average True Range (ATR) 0.07 0.10
MACD -0.03 0.02
Stochastic Oscillator 1.76 65.00

Price Performance

Historical Comparison
MRKR
ACCL

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

About ACCL Acco Group Holdings Limited Ordinary Shares

Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.

Share on Social Networks: